Use of Cefiderocol in the Management of Children With Infection or Colonization With Multi-drug Resistant Gram-negative Bacteria: A Retrospective, Single-center Case Series

Pediatr Infect Dis J. 2024 Aug 1;43(8):772-776. doi: 10.1097/INF.0000000000004347. Epub 2024 Apr 2.

Abstract

Cefiderocol, a novel siderophore cephalosporin, represents a treatment option for infections with multidrug-resistant Gram-negative bacteria, of which rates are rising worldwide. Clinical data on its use in children is limited. In our pediatric case series, the largest reported to date, cefiderocol seems safe and well tolerated, with more favorable clinical outcomes when compared to the literature reviewing adult cases.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents* / pharmacology
  • Anti-Bacterial Agents* / therapeutic use
  • Cefiderocol*
  • Cephalosporins* / pharmacology
  • Cephalosporins* / therapeutic use
  • Child
  • Child, Preschool
  • Drug Resistance, Multiple, Bacterial*
  • Female
  • Gram-Negative Bacteria* / drug effects
  • Gram-Negative Bacterial Infections* / drug therapy
  • Gram-Negative Bacterial Infections* / microbiology
  • Humans
  • Infant
  • Male
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Cefiderocol
  • Cephalosporins
  • Anti-Bacterial Agents